Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy and Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.
WilsonEGoswamiJBaquiAH, et al; ConquerRSV Study Group. Efficacy and safety of an mRNA-based RSV preF vaccine in older adults. N Engl J Med. 2023;389(24):2233-2244. doi:10.1056/NEJMoa2307079
5.
GoswamiJBaquiAHDoreskiPA, et al. Humoral immunogenicity of mRNA-1345 RSV vaccine in older adults. J Infect Dis. Published online June18, 2024. doi:10.1093/infdis/jiae316
6.
ShawCAEssinkBHarperC, et al. Safety and immunogenicity of an mRNA-based RSV vaccine including a 12-month booster in a phase 1 clinical trial in healthy older adults. J Infect Dis. Published online February2022, 2024.doi:10.1093/infdis/jiae081
7.
ShawCAMithaniRKapoorA, et al. Safety, tolerability, and immunogenicity of an mRNA-based RSV vaccine in healthy young adults in a phase 1 clinical trial. J Infect Dis. Published online January31, 2024. doi:10.1093/infdis/jiae035
8.
BrittonARoperLEKottonCN, et al. Use of respiratory syncytial virus vaccines in adults aged > 60 years: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2024. MMWR Morb Mortal Wkly Rep. 2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1
9.
ModernaTx, Inc. A study to investigate the immunogenicity and safety of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in high-risk adults. ClinicalTrials.gov identifier: NCT06067230. Updated August15, 2024. Accessed August 19, 2024. https://clinicaltrials.gov/study/NCT06067230
10.
MelgarMBrittonARoperLE, et al. Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices—United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4
11.
ModernaTX, Inc. A study of mRNA-1345 vaccine targeting respiratory syncytial virus in pregnant women and in infants born to vaccinated mothers. ClinicalTrials.gov identifier: NCT06143046. Updated May22, 2024. Accessed August 19, 2024. https://clinicaltrials.gov/study/NCT06143046
12.
KaslowDC.BLA approval letter: mRESVIA (respiratory syncytial virus vaccine) (BLA 125796/0). Food and Drug Administration. Published June14, 2024. Accessed August 19, 2024. https://www.fda.gov/media/179015/download?attachment
13.
ModernaTX, Inc. A study of mRNA-1345, an mRNA vaccine targeting respiratory syncytial virus, in children 2 to <18 years of age at high risk of respiratory syncytial virus. ClinicalTrials.gov identifier: NCT06097299. Updated August26, 2024. Accessed September 10, 2024. https://clinicaltrials.gov/study/NCT06097299
14.
ModernaTX, Inc. A study of mRNA-1345 vaccine targeting respiratory syncytial virus (RSV) in adults >50 years of age (RSVictory). ClinicalTrials.gov identifier: NCT05330975. Updated May10, 2024. Accessed August 19, 2024. https://clinicaltrials.gov/study/NCT05330975
15.
ModernaTX, Inc. A study to evaluate the safety and immune response of mRNA-1345, a vaccine targeting respiratory syncytial virus (RSV), when coadministered with a Fluzone HD, in adults ≥65 years of age. ClinicalTrials.gov identifier: NCT06060457. Updated June24, 2024. Accessed August 19, 2024. https://clinicaltrials.gov/study/NCT06060457
16.
ModernaTX, Inc. A safety, reactogenicity, and immunogenicity study of mRNA-1045 (influenza and respiratory syncytial virus [RSV]) or mRNA-1230 (influenza, RSV, and severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) vaccine in adults 50 to 75 years old. ClinicalTrials.gov identifier: NCT05585632. Updated March8, 2024. Accessed August 19, 2024. https://clinicaltrials.gov/study/NCT05585632
